Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amarillo BioSciences (AMAR) - Oral Interferon delivery sys -- Ignore unavailable to you. Want to Upgrade?

To: jack montgomery who wrote (191)	3/15/1999 8:12:00 AM
From: Tomas	Respond to of 201

I agree, I wish I could take advantage of the trading opportunity. I don't really have the facilities to play some of the lows and highs. Tom Yahoo as Chemgrat

To: jack montgomery who wrote (191)	4/1/1999 11:22:00 AM
From: Tomas	Read Replies (1) \| Respond to of 201

Hey Jack, The only thing I could pull from the a annual report that made me stop and think for a minute (to the negative). The principal budget items discussed above, along with other miscellaneous costs and expenses, will cause the Company to expend approximately $6.8 million in 1999, including the substantial expense of the Company's Phase III Sjogren's syndrome trial, and the additional personnel costs referred to under "Personnel", above. At December 31, 1998, the Company had available cash of $4,776,000. The Company will need to raise additional funds in order to completely execute its 1999 Plan. Should a commitment for additional funds not be obtained during the second quarter of 1999, the Company will take steps to curtail clinical trial expenditures and to reduce staff and administrative expenses. Management believes that based on the Company's ability to curtail clinical trial expense and to reduce staff and administration expenses, available funds are sufficient to meet its anticipated cash requirements for at least the next twelve months. It was written under the heading "Liquidity." Any thoughts? Be a real bitch to run out of money on the 3 yard line. I also hate to see them talk about the possibility of curtailing the clinical trial costs. Seems like that would just drag them out for longer than they have already taken. Tom